Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma

Yano, Hiroshi; Shiozaki, Hitoshi; Kobayashi, Kenji; Yano, Tokiharu; Tahara, Hideaki; Tamura, Shigeyuki; Mori, Takesada

doi:10.1002/1097-0142(19910101)67:1<91::aid-cncr2820670118>3.0.co;2-a

Cited by 86 publications

(43 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As done for breast cancer, HER2 staining was evaluated in a semiquantitative way with a cutoff of 10% '3 þ ' cells (PenaultLlorca et al, 2002). Tumour cells were considered to be 'EGFR positive' when their staining was more marked than that of the adjacent normal epithelium, in agreement with previous interpretations of EGFR in SCCO (Yano et al, 1991;Itakura et al, 1994). Whenever they had been found positive, we evaluated the percentage of cells displaying the same intensity of staining.…”

Section: Staining Evaluationsupporting

confidence: 80%

“…According to literature data, EGFR overexpression in this pathology ranges from 45.6 to 72.1% (Itakura et al, 1994;Shimada et al, 1999); our results are consistent with these findings. Most of the studies found a significant relationship to metastasis occurrence (Shimada et al, 1999), lymph node involvement and survival (Yano et al, 1991). By using EGF-binding assays, Ozawa and Coll (1989) and Mukaida and Coll (1991) drew the same conclusions, and so did Kitagawa and Coll (1996) from slot-blot hybridation experiments.…”

Section: Epidermal Growth Factor Receptor In Sccomentioning

confidence: 89%

See 1 more Smart Citation

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

et al. 2005

View full text Add to dashboard Cite

Squamous cell carcinoma of the oesophagus (SCCO) is still a pathology of bad prognosis. Specific therapies are now developed against epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2, c-kit receptor (CD117), vascular endothelial growth factor (VEGF) and p53 protein. This study was aimed at assessing their expression in a large series of SCCO, as well as their potential therapeutic interest in this pathology. Immunohistochemical expression of these factors was assessed retrospectively in 107 cases of SCCO with primary surgery, as well as their relationships to recurrence, metastasis and overall survival on a long-term follow-up. Human epidermal growth factor receptor 2 and CD117 were expressed in less than 3% of the cases. Epidermal growth factor receptor and p53 were overexpressed in 68.2 and 66.4% of the cases, and VEGF in 38.3%. Epidermal growth factor receptor overexpression was significantly related to vascular invasion (P ¼ 0.023). Its diffuse positivity was significantly related in multivariate analysis to higher local recurrence (P ¼ 0.006) and lower overall survival (P ¼ 0.003), in a subgroup of patients of poor outcome who had received postoperative adjuvant treatment. These results highlight the great potential prognostic and therapeutic interest of evaluating EGFR diffuse positivity in locally advanced SCCO.

show abstract

Section: Staining Evaluationsupporting

confidence: 80%

Section: Epidermal Growth Factor Receptor In Sccomentioning

confidence: 89%

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In particular, we and others have recently reported that the overexpression of EGFR of oesophageal SCC, partially accounted for by gene amplification, is found in 50 -70% (Itakura et al, 1994;Hanawa et al, 2006), and is indicative of a poor prognosis (Ozawa et al, 1989;Yano et al, 1991). Moreover, we showed that the overexpression of HER-2 in oesophageal SCC was found in 30.3% (Mimura et al, 2005b).…”

supporting

confidence: 66%

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma

et al. 2007

View full text Add to dashboard Cite

We previously reported that oesophageal squamous cell carcinoma (SCC) had a relatively high incidence of EGFR and HER-2 overexpression. Thus, anti-HER family targeting may become a promising approach to treat oesophageal SCC. In the present study, we investigated (a) the distribution of EGFR and HER-2 expression in oesophageal SCC (n ¼ 66) detected by immunohistochemistry and (b) cetuximab-and/or trastuzumab-mediated biological activity (antiproliferative effect by the MTT assay, apoptosis-inducing activity by the annexin V/propidium iodide assay, and antibody-dependent cellular cytotoxicity (ADCC) by the 51 Cr-release assay) against oesophageal SCC cell lines with various levels of EGFR and HER-2. Twelve of the 66 patients (18%) showed both EGFR-and HER-2 expression. Out of both EGFR-and HER-2-positive cases, nine cases (75%) showed EGFR and HER-2 expression in individually distinct regions. Furthermore, the combination of cetuximab and trastuzumab could induce synergistic antiproliferative effects and additional ADCC activities against not all, but several oesophageal SCC cell lines with EGFR and HER-2 expression. The combination of cetuximab and trastuzumab may be useful in the treatment of oesophageal SCC with EGFR and HER-2 expression.

show abstract

“…Patients who had tumors that expressed EGFR had shorter disease-free and overall survival compared with patients who had EGFR-negative tumors, but EGFR expression was not an independent prognostic indicator for either parameter in multivariate analysis. Although there have been several studies of EGFR expression in esophageal squamous cell carcinomas, 21,[25][26][27][35][36][37][38] studies of the role of EGFR in esophageal adenocarcinomas have been limited. 28,29,39 Similar to our studies, the majority of the esophageal adenocarcinomas in previous studies were from the lower one-third of the esophagus or from the GEJ.…”

Section: Discussionmentioning

confidence: 99%

“…10 Protein overexpression or gene amplification of EGFR has been reported in several human tumors of epithelial origin, including head and neck, [11][12][13] thyroid, 14 breast, 15,16 ovarian, 17 , colon, [18][19][20][21] cervix, bladder, 22 stomach, and lung 23 cancers. In a subset of these tumors, most notably breast cancer, 16,19,24 colorectal cancer, [18][19][20][21] and esophageal squamous cell carcinoma, 21,25,26 increased EGFR expression has been associated with advanced disease, development of metastases, and poor clinical prognosis. Whether EGFR plays a similar role in esophageal adenocarcinoma is not clear.…”

mentioning

confidence: 99%

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas

Wang

Choi

et al. 2007

Cancer

183

124

View full text Add to dashboard Cite

BACKGROUND.The prognosis for patients with esophageal and esophagogastric junction (EGJ) adenocarcinoma remains poor, even after surgical resection. Pathologic assessment of depth of invasion and lymph node status are the primary prognostic factors in these patients. In patients with esophageal squamous cell carcinoma, increased epidermal growth factor receptor (EGFR) expression has been associated with a worse prognosis. It is not known whether EGFR plays a similar role in esophageal and EGJ adenocarcinomas.METHODS.To address this issue, the authors studied tumor specimens from 103 patients with surgically resected esophageal and EGJ adenocarcinomas (9 patients with stage I disease, 23 patients with stage II disease, 57 patients with stage III disease, and 14 patients with stage IV disease). The expression of EGFR was assessed by immunohistochemical analysis of tissue microarrays. Tumors were considered positive for EGFR expression when >5% of tumor cells were stained and negative when ≤5% of tumor cells were stained.RESULTS.EGFR was expressed in 33 of 103 adenocarcinomas (32%) and was correlated with higher pathologic tumor (T) classification (P = .02), the presence of lymph node metastasis (P = .01), and higher pathologic tumor, lymph node, metastasis classification (P = .02). EGFR expression also was correlated with shorter disease‐free and overall survival in univariate analyses (P = .001 and P = .004, respectively), and there was a trend toward a correlation between EGFR expression and shorter disease‐free survival in multivariate analyses (P = .07 and P = .08). The results demonstrated that EGFR expression in esophageal adenocarcinomas was correlated with advanced pathologic tumor classification and lymph node metastasis. EGFR expression also was correlated with poor disease‐free and overall survival, but that correlation was not independent of T classification.CONCLUSIONS.The current findings suggested that EGFR expression correlates with poor prognostic factors and may be used to predict patient outcomes. Cancer 2007. © 2007 American Cancer Society.

show abstract

Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma

Cited by 86 publications

References 17 publications

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas

Contact Info

Product

Resources

About